Loading…
Metagenomi Therapeutics, Inc. is projected to rise to $1.33 by 2027, a +5% move from its current price of $1.27. MGX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.24 | $1.27 | $1.30 | +0.02% |
| Jul 14 | $1.23 | $1.27 | $1.31 | +0.04% |
| Jul 15 | $1.22 | $1.27 | $1.33 | +0.05% |
| Jul 16 | $1.21 | $1.27 | $1.33 | +0.07% |
| Jul 17 | $1.20 | $1.27 | $1.34 | +0.09% |
| Jul 18 | $1.20 | $1.27 | $1.35 | +0.11% |
| Jul 19 | $1.19 | $1.27 | $1.36 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.19 | $1.27 | $1.36 | +0.13% |
| Week 2 | $1.16 | $1.27 | $1.39 | +0.26% |
| Week 3 | $1.14 | $1.27 | $1.42 | +0.38% |
| Week 4 | $1.12 | $1.28 | $1.45 | +0.51% |
| Week 5 | $1.11 | $1.28 | $1.48 | +0.64% |
| Week 6 | $1.09 | $1.28 | $1.50 | +0.77% |
| Week 7 | $1.08 | $1.28 | $1.52 | +0.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Metagenomi Therapeutics, Inc. is an in vivo genome editing company that develops curative genetic medicines in the United States. Its lead development program MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia.
The company has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. Metagenomi Therapeutics, Inc.
was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
MGX is currently priced at $1.24 and has a market cap of $46.68M, ranking 4614 by market capitalization. The stock sits in the Healthcare category. The near-term forecast suggests a neutral stance in 2026, with min $1.14, avg $1.24, max $1.54 and ROI 0.
The longer-term forecast shows a bullish path later in the horizon, with the average price rising to $4.20 by 2050 and a max near $7.27, reflecting meaningful upside potential.
A major floor 20.5% below — a decisive break under it would weaken the trend.
The nearest floor, 10.2% below — buyers have tended to step in here.
The nearest ceiling, 10.2% above — a clean break opens room to run.
A major ceiling 38.6% above — clearing it would confirm fresh momentum.
Key MGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.28 | Sell | $1.27 | Buy |
| MA 10 | $1.25 | Buy | $1.26 | Buy |
| MA 20 | $1.22 | Buy | $1.25 | Buy |
| MA 50 | $1.29 | Sell | $1.29 | Sell |
| MA 100 | $1.38 | Sell | $1.39 | Sell |
| MA 200 | $1.69 | Sell | $1.61 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.53 | Neutral |
| Stoch RSI (14) | 68.03 | Neutral |
| CCI (20) | 81.81 | Neutral |
| Williams %R (14) | -38.46 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 2.42 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 61.54 | Neutral |
| TRIX (15) | -0.23 | Sell |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 61.84 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 1.30 | Sell |
| ADX (14) | 12.77 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is Bearish in sentiment. The RSI14 is 50, with a SMA50 of $1.35 and a SMA200 of $1.73. The security has support at $1.14 and resistance at $1.40, with a 30-day range from $1.07 to $1.44. Annualized volatility stands at 40, signaling notable near‑term price variability.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.14 | $1.27 | $1.59 | 0% | Neutral | |
| $1.07 | $1.33 | $1.74 | +5% | Neutral | |
| $1.06 | $1.35 | $1.83 | +6% | Neutral | |
| $1.05 | $1.37 | $1.90 | +7% | Neutral | |
| $0.9977 | $1.32 | $1.88 | +4% | Neutral | |
| $1.11 | $1.50 | $2.17 | +18% | Neutral | |
| $1.31 | $1.79 | $2.64 | +41% | Bullish | |
| $1.31 | $1.81 | $2.71 | +42% | Bullish | |
| $1.34 | $1.88 | $2.86 | +48% | Bullish | |
| $1.32 | $1.87 | $2.88 | +47% | Bullish | |
| $1.85 | $2.78 | $4.53 | +119% | Bullish | |
| $2.55 | $4.24 | $7.51 | +234% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.14 | $1.27 | $1.55 | +0.00% |
| August 2026 | $1.12 | $1.31 | $1.59 | +3.47% |
| September 2026 | $1.09 | $1.29 | $1.57 | -1.73% |
| October 2026 | $1.10 | $1.30 | $1.60 | +1.02% |
| November 2026 | $1.10 | $1.31 | $1.63 | +0.80% |
| December 2026 | $1.06 | $1.28 | $1.59 | -2.77% |
Click any year to see its month-by-month MGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect MGX to range from $1.14 to $1.59 through 2026. The $1.27 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The MGX price prediction for 2027 points to an average of $1.33 (low $1.07, high $1.74) — a potential gain of +5% on today's $1.27. Price action looks broadly range-bound.
In 2028, MGX is projected to trade between $1.06 and $1.83, averaging $1.35 — a potential gain of +6% from today's $1.27. That is up +2% on the projected 2027 average. A consolidation phase looks the most probable path here.
Metagenomi Therapeutics, Inc.'s 2029 outlook centres on $1.37, within a $1.05 to $1.90 range. That is up +1% on the projected 2028 average. That marks a +7% change versus current levels. Price action looks broadly range-bound.
By 2030, MGX could reach as high as $1.88, with a base case around $1.32 and support toward $0.9977 — roughly +4% from $1.27. A consolidation phase looks the most probable path here.
Expect MGX to range from $1.11 to $2.17 through 2031. The $1.50 average target implies a +18% move from current prices. That is up +14% on the projected 2030 average. Price action looks broadly range-bound.
The MGX price prediction for 2032 points to an average of $1.79 (low $1.31, high $2.64) — a potential gain of +41% on today's $1.27. Buyers look set to stay in control over this stretch.
In 2033, MGX is projected to trade between $1.31 and $2.71, averaging $1.81 — a potential gain of +42% from today's $1.27. That is up +1% on the projected 2032 average. Momentum favours further upside here.
Metagenomi Therapeutics, Inc.'s 2034 outlook centres on $1.88, within a $1.34 to $2.86 range. That is up +4% on the projected 2033 average. That marks a +48% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, MGX could reach as high as $2.88, with a base case around $1.87 and support toward $1.32 — roughly +47% from $1.27. Momentum favours further upside here.
Expect MGX to range from $1.85 to $4.53 through 2040. The $2.78 average target implies a +119% move from current prices. That is up +49% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The MGX price prediction for 2050 points to an average of $4.24 (low $2.55, high $7.51) — a potential gain of +234% on today's $1.27. Momentum favours further upside here.
Investing $1,000 in MGX today (≈ 787.401575 MGX) could be worth
$3,336.71
+$2,336.71 (+234%) by 2050 · US Dollar
Based on the average projected MGX price of $4.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MGXwould be worth at today's price.
$1,000 invested in MGX on Jul 10, 2025 (≈ 452.48868 MGX) would be worth
$574.66
-$425.34 (-42.5%) today · 0.57× · US Dollar
Based on a MGX entry price of $2.21 vs. today's $1.27.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.26 | $1,007.94 | +0.8% |
| 1 month ago | $1.23 | $1,032.52 | +3.3% |
| 3 months ago | $1.38 | $920.29 | -8.0% |
| 6 months ago | $1.75 | $725.71 | -27.4% |
| 1 year ago | $2.21 | $574.66 | -42.5% |
| All time (2.4y) ago | $10.31 | $123.18 | -87.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MGX forecast.
Our base-case forecast reaches $2.50 around 2040.
Implied market cap at $2.50: $94.12M
Looking out across the multi-year forecast, the path shifts from Neutral in the 2026–2031 window to Bullish from 2032 onward. In 2030 the average forecast price is $1.34, with a min of $1.02 and a max of $1.88, and ROI of 7.8. By 2032 the forecast strengthens, with an average of $1.75 and a Bullish sentiment, and it remains Bullish through 2033–2035 with steady gains.
The 2040 forecast shows an average of $2.72 and a max of $4.35, with ROI of 119.4. By 2050 the average is $4.20, the max $7.27, and ROI reaches 238.5, continuing with a Bullish outlook. These figures imply a substantial upside if the longer-term scenario plays out, but they are estimates, not guarantees, and carry inherent investment risk.
Tap a question to reveal the answer.
Avg $1.34, min $1.02, max $1.88, ROI 7.8, sentiment NEUTRAL.
The forecast shows Neutral from 2026 to 2031, turning Bullish from 2032 onward, with average prices rising to $1.75 by 2032 and $4.20 by 2050, and ROI up to 238.5 by 2050.
Yes, the 2050 max forecast is $7.27, indicating potential to exceed $5 under the modeled scenario.
Current price is $1.24 and market cap is $46.68M.
The forecast turns Bullish starting in 2032 and remains Bullish through 2050.
Metagenomi Therapeutics, Inc. Community Discussion
0Share your Metagenomi Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.